Antiangiogenic activity of zinc and zinc-sorafenib combination using the chick chorioallantoic membrane assay: a descriptive study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20171559Keywords:
Aantiangiogenic, Chick chorioallantoic membrane assay, Sorafenib, ZincAbstract
Background: Zinc, a trace element, is known for downregulating several proangiogenic growth factors and cytokines. However, its antiangiogenic activity is not adequately studied. The present study was aimed to evaluate the possible antiangiogenic activity of zinc via the chick chorioallantoic membrane (CAM) assay. Also, the antiangiogenic activity of the combination therapy of zinc with various doses of sorafenib, a tyrosine kinase inhibitor, was evaluated.
Methods: A pilot study was initially conducted so as to select suitable doses of zinc and sorafenib. The antiangiogenic activity after combining zinc 2.5 μg/embryo with sorafenib 1, and 2 μg/embryo was also evaluated. The antiangiogenic activity was quantified in terms of total length of blood vessels, number of junctions, number of branching points, and mean length of the blood vessels.
Results: Zinc 2.5 μg/embryo showed significant (p <0.05) antiangiogenic activity, as compared to the control group. However, its effect was not comparable to that of sorafenib 2 μg/embryo. The combination of zinc 2.5 μg/embryo with sorafenib 2 μg/embryo did not show an additive/synergistic effect. The combination of zinc 2.5 μg/embryo with sorafenib 1 μg/embryo produced an antiangiogenic activity which was comparable (p >0.05) to that of sorafenib 2 μg/embryo.
Conclusions: Zinc caused significant antiangiogenic activity in the CAM assay. The lack of addition/synergism in the zinc-sorafenib combination could have been due to the variability in the dose/ratio selection. Addition of zinc to sorafenib therapy could improve treatment tolerability, reduce cost of therapy, and reduce the emergence of drug resistance. Future mechanistic studies could identify the exact pharmacodynamics of zinc as an angiogenesis inhibitor.
References
Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014;17:471-94.
Chabner BA, Barnes J, Neal J, Olson E, Mujagic H, Sequist L, et al. Targeted therapies: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines. In: Brunton LL (ed). Goodman and Gillman’s The Pharmacolological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill. 2011:1731-53.
Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8:210-21.
van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev. 2015;67:441-61.
Golovine K, Uzzo RG, Makhov P, Crispen PL, Kundle D, Kolenko M. Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6, IL-8 in prostate cancer cells via NF-kappaB-dependent pathway. Prostate. 2008;68:1443-9.
Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, et al. Zinc downregulates HIF-1α and inhibits its activity in tumor cells In Vitro and In Vivo. PLos One. 2010;5:15048.
Dhawan DK, Chadha VD. Zinc: a promising agent in dietary chemoprevention of cancer. Indian J Med Res. 2010;132:676-82.
Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, et al. Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J Cancer. 2011;131:562-8.
Ilouz R, Kaidanovich O, Gurwitz D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight to the insulin-mimetic action of zinc. Biochem Biophys Res Commun. 2002;295:102-6.
Ribatti D, Vacca A, Roncali L, Dammacco F. The chick chorioallantoic membrane as a model for in vivo research on anti-angiogenesis. Curr Pharm Biotechnol. 2000;1:73-82.
Khoo CP, Micklem K, Watt SM. A comparison of methods for quantifying angiogenesis in the matrigel assay In Vitro. Tissue Eng Part C Methods. 2011;17:895-906.
Uzzo RG, Crispen PL, Golovine K, Makhov P, Horwitz EM, Kolenko VM. Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostrate progression. Carcinogenesis. 2006;27:1980-90.
Nowak-Sliwinska P, Weiss A, van Beijnum JR, Wong TJ, Ballini JP, Lovisa B, et al. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J Cell Mol Med. 2012;16:1553-62.
Bozym RA, Chimienti F, Giblin LJ, Gross GW, Korichneva I, Li Y, et al. Free zinc outside a narrow concentration range are toxic to a variety of cells in vitro. Exp Biol Med (Maywood). 2010;235:742-50.
Barui AK, Veeriah V, Mukherjee S, Manna J, Patel AK, Patra S, et al. Zinc oxide nanoflowers make new blood vessels. Nanoscale. 2012;4:7861-9.
Kaji T, Fujiwara Y, Yamamoto C, Sakamoto M, Kozuka H. Stimulation by zinc of cultured vascular endothelial cell proliferation: possible involvement of endogenous basic fibroblast growth factor. Life Sci 1994;55:1781-7.
Pasqualini R, Barbas CF 3rd, Arap W. Vessel maneuvers: zinc fingers promote angiogenesis. Nat Med. 2002;8:1353-4.
Prasad AS. Effects of zinc deficiency on Th1 and Th2 cytokine shifts. J Infect Dis. 2000;183:62-8.
Saghri MA, Astaourian A, Orangi J, Sorenson CM, Sheibani N. Functional role of inorganic trace elements in angiogenesis-Part II: Cr, Si, Zn, Cu, and S. Crit Rev Oncol Hematol. 2015;96:143-55.
Boehm T, O’reilly MS, Keough K, Shiloach J, Shapiro R, Folkman J. Zinc binding of endostatin is essential for its antiangiogenic activity. Biochem Biophys Res Commun. 1998;252:190-4.
Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2:213-9.
Tada-Oikawa S, Ichihara G, Suzuki Y, Izuoka K, Wu W, Yamada Y, et al. Zn (II) released from zinc oxide nano/micro particles suppresses vasculogenesis in human endothelial colony-forming cells. Toxicology Reports. 2015;2:692-701.
Osterhoudt KC, Penning TM. Drug toxicity and poisoning. In: Brunton LL (ed). Goodman and Gillman’s The Pharmacolological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011:73-87.
Albiges L, Choueiri T, Escudier B, Gaisky M, George D, Hofmann F, et al. A systematic review of sequencing and combination of systemic therapy in metastatic renal cancer. Eur Urol. 2015;67:100-10.
Kawazoe H, Bilim VN, Ugolkov AV, Yuuki K, Naito S, Nagaoka A, et al. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcninoma (RCC). Biochem Biophys Res Commun. 2012;423:490-5.
